243 related articles for article (PubMed ID: 8212422)
1. [Immunotherapy of superficial bladder cancer].
Schmitz-Dräger BJ; Schattka SO; Ebert T
Urologe A; 1993 Sep; 32(5):374-81. PubMed ID: 8212422
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of bladder cancer.
Nseyo UO; Lamm DL
Semin Surg Oncol; 1997; 13(5):342-9. PubMed ID: 9259090
[TBL] [Abstract][Full Text] [Related]
3. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
[TBL] [Abstract][Full Text] [Related]
4. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist?. analysis of a quarter century of literature.
Saint F; Salomon L; Quintela R; Cicco A; Hoznek A; Abbou CC; Chopin DK
Eur Urol; 2003 Apr; 43(4):351-60; discussion 360-1. PubMed ID: 12667715
[TBL] [Abstract][Full Text] [Related]
5. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
6. [Cytokine therapy of superficial bladder carcinoma. Mechanisms of action and results of therapy].
Otto T; Kälble T
Urologe A; 1994 Nov; 33(6):540-6. PubMed ID: 7817454
[TBL] [Abstract][Full Text] [Related]
7. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
8. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
Yutkin V; Pode D; Pikarsky E; Mandelboim O
J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
[TBL] [Abstract][Full Text] [Related]
9. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder. A metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy.
Montie JE
J Urol; 2005 Nov; 174(5):1783-4. PubMed ID: 16217285
[No Abstract] [Full Text] [Related]
10. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
Steinbach F; Schuster F
Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
[TBL] [Abstract][Full Text] [Related]
11. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
12. Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors.
Morales A; Eidinger D; Bruce AW
J Urol; 2017 Feb; 197(2S):S142-S145. PubMed ID: 28012770
[TBL] [Abstract][Full Text] [Related]
13. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
Demkow T; Alter A; Wiechno P
Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
[TBL] [Abstract][Full Text] [Related]
14. The management of superficial bladder cancer.
Dalbagni G
Nat Clin Pract Urol; 2007 May; 4(5):254-60. PubMed ID: 17483810
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
[TBL] [Abstract][Full Text] [Related]
16. [Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH. A prospective randomized study].
Kälble T; Möhring K; Ikinger U; Riedasch G; Staehler G
Urologe A; 1991 Mar; 30(2):118-21. PubMed ID: 2058066
[TBL] [Abstract][Full Text] [Related]
17. [BCG-instillation therapy in superficial bladder tumor--host immune response elicited by local application of BCG].
Hayakawa M; Hatano T; Saito S; Miyazato T; Nakayama M; Igarashi M; Saita H
Nihon Hinyokika Gakkai Zasshi; 1987 Nov; 78(11):1972-81. PubMed ID: 3502480
[No Abstract] [Full Text] [Related]
18. [Studies on stimulation of immunological responses resulting from intravesical BCG instillation in patients with bladder carcinomas].
Tachibana M; Jitsukawa S; Deguchi N; Tazaki H
Nihon Hinyokika Gakkai Zasshi; 1988 Oct; 79(10):1680-5. PubMed ID: 3251104
[No Abstract] [Full Text] [Related]
19. Reactive arthritis following BCG immunotherapy for bladder carcinoma.
Tinazzi E; Ficarra V; Simeoni S; Peterlana D; Lunardi C
Clin Rheumatol; 2005 Aug; 24(4):425-7. PubMed ID: 15660288
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy with bacille Calmette-Guérin in patients with superficial transitional cell carcinoma of the bladder associated with bilharziasis.
Wishahi MM; Ismail IM; el-Sherbini M
Br J Urol; 1994 Jun; 73(6):649-54. PubMed ID: 8032832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
